Revvity (RVTY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
16 Mar, 2026Executive summary
The annual meeting will be held virtually on April 28, 2026, with shareholders able to vote electronically or by proxy as of the March 2, 2026 record date.
Key agenda items include director elections, auditor ratification, executive compensation, by-law amendment for special meetings, and a shareholder proposal on executive stock retention.
The board recommends voting for all management proposals and against the shareholder proposal.
Voting matters and shareholder proposals
Election of ten directors for one-year terms.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal 2026.
Advisory vote on executive compensation (say-on-pay).
Amendment to by-laws to allow shareholders with 25% ownership to call special meetings, reducing the threshold from 40%.
Shareholder proposal requiring executives to retain a significant percentage of stock acquired through equity pay programs; board recommends against.
Board of directors and corporate governance
Board consists of ten members, nine of whom are independent; Non-Executive Chair structure in place.
Annual board self-evaluation and review of independence.
Committees: Audit, Compensation & Benefits, Nominating & Corporate Governance, all comprised of independent directors.
Shareholders can recommend or directly nominate director candidates.
Proxy access allows groups owning 3%+ for three years to nominate directors.
Latest events from Revvity
- Targeting 6%-8% organic growth and margin expansion through innovation and operational synergies.RVTY
Investor Day 20248 Jul 2026 - Life sciences and software growth accelerate as pharma biotech recovers and AI adoption expands.RVTY
Citi Annual Global Healthcare Conference 20258 Jul 2026 - Q3 revenue up 2% to $684M, adjusted EPS $1.28, and new $1B share repurchase program.RVTY
Q3 20248 Jul 2026 - Strong growth, portfolio optimization, and innovation drive optimism for sustained margin expansion.RVTY
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Divestiture of China immunodiagnostics boosts growth outlook; AI and software launches drive optimism.RVTY
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenue up 7%, strong organic growth, and China divestiture shapes 2026 outlook.RVTY
Q1 202612 May 2026 - Board elections, auditor ratification, and bylaw changes passed; stock retention proposal failed.RVTY
AGM 202628 Apr 2026 - Key votes include director elections, auditor ratification, and by-law amendment for special meetings.RVTY
Proxy Filing16 Mar 2026 - AI-powered Signals launches and new revenue models drive growth amid cautious market outlook.RVTY
Barclays 28th Annual Global Healthcare Conference10 Mar 2026